Imaging hypoxia in tumors
References (98)
- et al.
Clinical experience with radiation enhancement by hyperbaric oxygen in children with recurrent neuroblastoma stage IV
Eur J Cancer
(1995) Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
Mol Med Today
(2000)- et al.
Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix
Radiother Oncol
(1993) - et al.
Heterogeneity of polarographic oxygen tension measurements in cervix cancer: An evaluation of within and between tumor variability, probe position, and track depth
Int J Radiat Oncol Biol Phys
(1997) - et al.
Oxygenation predicts radiation response and survival in patients with cervical cancer
Radiother Oncol
(1998) - et al.
Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck
Radiother Oncol
(1996) - et al.
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
Int J Radiat Oncol Biol Phys
(1997) - et al.
Cervix cancer oxygenation measured following external radiation therapy
Int J Radiat Oncol Biol Phys
(1998) - et al.
Hypoxia marker labeling in tumor biopsies: Quantification of labeling variation and criteria for biopsy sectioning
Radiother Oncol
(1997) - et al.
Pimonidazole: A novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma
Gynecol Oncol
(1998)
An efficient radiosynthesis of [18F]fluoromisonidazole
Appl Radiat Isot
Synthesis of new hypoxia markers EF1 and [18F]-EF1
Appl Radiat Isot
[18F]-EF5, a marker for PET detection of hypoxia: Synthesis of precursor and a new fluorination procedure
Appl Radiat Isot
Single-photon emission computed tomography and positron-emission tomography assays for tissue oxygenation
Semin Radiat Oncol
A rapid and simple assay to determine the blood and urine concentrations of 1-(5-[123/125I] iodo-5-deoxyarabinofuranosyl)-2-nitroimidazole, a hypoxic cell marker
J Pharmaceut Biomed Anal
Synthesis, radiolabeling, and biodistribution of putative metabolites of iodoazomycin arabinoside
Nucl Med Biol
An improved synthesis of α-AZA, α-AZP and α-AZG, the precursors to clinical markers of tissue hypoxia
Tetrahedron Lett
Measuring hypoxia and predicting tumor radioresistance with nuclear medicine assays
Radiother Oncol
Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazale, with unlabelled nitroaromatics
Biochem Pharmacol
Role of NADPH cytochrome P450 reductase in the hypoxic accumulation and metabolism of BRU59-21, a technetium-99m-nitroimidazole for imaging tumor hypoxia
Biochem Pharmacol
Technetium-99m-cyclam AK 2123: A novel marker for tumor hypoxia
Appl Radiat Isot
Evaluation of Cu-PTSM as a tracer of tumor perfusion: Comparison with labeled microspheres in spontaneous canine neoplasms
Nucl Med Biol
Towards new transition metal-based hypoxic selective agents for therapy and imaging
J Inorg Biochem
Studies of 99mTc-BnAO (HL-91): A non-nitroaromatic compound for hypoxic cell detection
Int J Radiat Oncol Biol Phys
Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo
Int J Radiat Oncol Biol Phys
The development of 99mTc-analog of Cu-DTS as an agent for imaging hypoxia
Nucl Med Biol
Imaging of hypoxia in human tumors with [18F]-fluoromisonidazole
Int J Radiat Oncol Biol Phys
Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography
Int J Radiat Oncol Biol Phys
Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: A pretherapy study of 37 patients
Int J Radiat Oncol Biol Phys
A comparison in individual murine tumors of techniques for measuring oxygen levels
Int J Radiat Oncol Biol Phys
The potential for myocardial imaging with hypoxia markers
Semin Nucl Med
Magnetic resonance imaging techniques for monitoring changes in tumor oxygenation and blood flow
Semin Radiat Oncol
Selective boosting of tumor subvolumes
Int J Radiat Oncol Biol Phys
The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy
Br J Radiol
Definitive evidence for hypoxic cells influencing cure in cancer therapy
Br J Cancer
Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors
Oncol Res
Improved response of colon cancer xenografts to radioimmunotherapy with pentoxifylline treatment
Eur J Nucl Med
The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
Cancer Res
Hypoxia mediated selection of cells with diminished apoptotic potential in solid tumors
Nature
Genetic instability induced by the tumor microenvironment
Cancer Res
Optical sensor-based oxygen tension measurements correspond with hypoxia marker binding in three human tumor xenograft lines
Radiat Res
Tumor oxygenation predicts for likelihood of distant metastases in human soft tissue sarcoma
Cancer Res
Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age
Cancer
Hypoxia-induced treatment failure in advanced squamous cell carcinoma of the uterine cervix is primarily due to hypoxia-induced radiation resistance rather than hypoxia-induced metastasis
Br J Cancer
Hypoxic sensitizers—Implications for radiation therapy
N Engl J Med
Use of 2-nitroimidazoles as bioreductive markers for tumor hypoxia
Anti-Cancer Drug Des
Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]
Br J Cancer
Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker
Cancer Res
Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas
Br J Cancer
Cited by (112)
Azo-based small molecular hypoxia responsive theranostic for tumor-specific imaging and therapy
2018, Journal of Controlled ReleaseKit formulation for preparation and biological evaluation of a novel <sup>99m</sup>Tc-oxo complex with metronidazole xanthate for imaging tumor hypoxia
2016, Nuclear Medicine and BiologyCitation Excerpt :Up to now, much effort has been made to develop radiolabeled hypoxia imaging agents. Among them, nitroimidazole derivates are thought to undergo bioreduction reaction in the hypoxic cell and thus can be retained in hypoxic tissue [2,3]. Thus, different kinds of PET and SPECT tracers containing nitroimidazole group have been evaluated as hypoxia imaging agents [4–24].
Optimizing hypoxia detection and treatment strategies
2015, Seminars in Nuclear MedicineCitation Excerpt :The first F-18–labeled drug to be clinically tested was 1-(2-nitro-1-H-imidazol-1-yl)-3-fluoro-2-propan-2-ol (FMISO), and it remains the most extensively tested agent (for review see 37,44). Owing to some perceived problems with FMISO׳s stability in vivo45 and failure to achieve image intensities in humans comparable to what had been achieved in animal models, or for example the very high intensity contrast seen with FDG, many additional nitroimidazoles have been synthesized for the purpose of NII and several have progressed from preclinical development to therapeutic trials. These include 1-(2-nitro-1-H-imidazol-1-yl)-4-fluoro-butane-2,3-diol (FETNIM), 2-(2-nitro-1-H-imidazol-1-yl)-N-(2-fluoroethyl)-acetamide (FETA), 1-(6-deoxy-6-iodo-b-d-galactopyranosyl)-2-nitroimidazole (IAZGP), EF5, EF3, IAZA, 1-(5-fluoro-5-deoxy-a-d-arabinofuranosyl)-2-nitroimidazole (FAZA), HX4, and others—for review of structures and properties see Horsman et al.46
Recent Advances of <sup>68</sup>Ga-Labeled PET Radiotracers with Nitroimidazole in the Diagnosis of Hypoxia Tumors
2023, International Journal of Molecular Sciences